AR082494A1 - Composicion en torta y en suspension con contenido de derivado de carbostirilo y derivado de aceite de silicona y/o aceite de silicona - Google Patents
Composicion en torta y en suspension con contenido de derivado de carbostirilo y derivado de aceite de silicona y/o aceite de siliconaInfo
- Publication number
- AR082494A1 AR082494A1 ARP110103020A ARP110103020A AR082494A1 AR 082494 A1 AR082494 A1 AR 082494A1 AR P110103020 A ARP110103020 A AR P110103020A AR P110103020 A ARP110103020 A AR P110103020A AR 082494 A1 AR082494 A1 AR 082494A1
- Authority
- AR
- Argentina
- Prior art keywords
- silicone oil
- active ingredient
- derivative
- suspension
- parts
- Prior art date
Links
- 229920002545 silicone oil Polymers 0.000 title abstract 16
- 239000000725 suspension Substances 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 14
- 239000002245 particle Substances 0.000 abstract 5
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 abstract 3
- 229960004372 aripiprazole Drugs 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000002612 dispersion medium Substances 0.000 abstract 3
- 239000011164 primary particle Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Colloid Chemistry (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Disinfection, Sterilisation Or Deodorisation Of Air (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- Degasification And Air Bubble Elimination (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
Reivindicación 1: Un método para evitar que las partículas del ingrediente activo se aglomeren en una suspensión; la suspensión contiene un ingrediente activo y derivado de aceite de silicona y/o aceite de silicona en un medio de dispersión; el ingrediente activo es, al menos, un miembro seleccionado entre el grupo que consiste en aripiprazol y un compuesto representado por la fórmula estructural (1), el ingrediente activo se encuentra en forma de partículas que tienen una media del tamaño de partícula primaria de 0,1 mm o superior, e inferior a 200 mm; el método comprende mezclar el ingrediente activo con el derivado de aceite de silicona y/o aceite de silicona en un medio de dispersión, en tal manera que el derivado de aceite de silicona y/o aceite de silicona estén contenidos en una cantidad comprendida entre 0,001 y 0,2 partes en peso con relación a 100 partes en peso del ingrediente activo contenido en la suspensión.Reivindicación 4: Una suspensión que comprende un ingrediente activo y derivado de aceite de silicona y/o aceite de silicona en un medio de dispersión; el ingrediente activo es, al menos, un miembro seleccionado entre el grupo que consiste en aripiprazol y un compuesto representado por la fórmula estructural (1) el ingrediente activo se encuentra en forma de partículas que tienen una media del tamaño de partícula primaria de 0,1 mm o superior, e inferior a 200 mm y en donde el derivado de aceite de silicona y/o aceite de silicona están contenidos en una cantidad comprendida entre 0,001 y 0,2 partes en peso con relación a 100 partes en peso del ingrediente activo contenido en la suspensión. Reivindicación 7: Una composición en torta que comprende un ingrediente activo y derivado de aceite de silicona y/o aceite de silicona; el ingrediente activo es, al menos, un miembro seleccionado entre el grupo que consiste en aripiprazol y un compuesto representado por la siguiente fórmula estructural (1) el ingrediente activo se encuentra en forma de partículas y tiene una media del tamaño de partícula de 0,1 mm o superior, e inferior a 200 mm y en donde el derivado de aceite de silicona y/o aceite de silicona está contenido en una cantidad comprendida entre 0,001 y 0,2 partes en peso con relación a 100 partes en peso del ingrediente activo contenidos en la composición en torta.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010187107 | 2010-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082494A1 true AR082494A1 (es) | 2012-12-12 |
Family
ID=44645176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103020A AR082494A1 (es) | 2010-08-24 | 2011-08-19 | Composicion en torta y en suspension con contenido de derivado de carbostirilo y derivado de aceite de silicona y/o aceite de silicona |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9511022B2 (es) |
| EP (1) | EP2552420B1 (es) |
| JP (1) | JP5575269B2 (es) |
| KR (1) | KR101461769B1 (es) |
| CN (1) | CN103025318B (es) |
| AR (1) | AR082494A1 (es) |
| AU (1) | AU2011294201B2 (es) |
| BR (1) | BR112012028368B8 (es) |
| CA (1) | CA2796755C (es) |
| CO (1) | CO6640304A2 (es) |
| ES (1) | ES2685469T3 (es) |
| IL (1) | IL222628A (es) |
| MX (1) | MX344235B (es) |
| MY (1) | MY174552A (es) |
| NZ (1) | NZ603076A (es) |
| RU (1) | RU2535089C2 (es) |
| SG (1) | SG184879A1 (es) |
| TW (1) | TWI589301B (es) |
| UA (1) | UA107031C2 (es) |
| WO (1) | WO2012026562A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3190B1 (ar) * | 2011-10-19 | 2018-03-08 | Otsuka Pharma Co Ltd | محلول للتناول عن طريق الفم |
| TWI562991B (en) | 2012-04-23 | 2016-12-21 | Otsuka Pharma Co Ltd | Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same |
| JOP20200109A1 (ar) * | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| AR091349A1 (es) * | 2012-04-30 | 2015-01-28 | Otsuka Pharma Co Ltd | Formulacion oral |
| CN106474058B (zh) * | 2015-08-31 | 2020-01-07 | 南京诺瑞特医药科技有限公司 | 具有延长的保质期的阿立哌唑可注射悬浮液制剂 |
| EP3577111A1 (en) | 2017-02-02 | 2019-12-11 | Hexal Aktiengesellschaft | Crystalline brexpiprazole |
| CN114786724A (zh) | 2019-12-16 | 2022-07-22 | 尼普洛株式会社 | 防聚集剂以及使用该防聚集剂的药物组合物和医疗用设备 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2827566A1 (de) | 1978-06-23 | 1980-01-10 | Boehringer Mannheim Gmbh | 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung |
| US4225456A (en) * | 1978-11-06 | 1980-09-30 | Diamond Shamrock Corporation | Water-in-oil emulsion defoamer compositions, their preparation and use |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| JP3332426B2 (ja) | 1992-10-02 | 2002-10-07 | 太田製薬株式会社 | 大腸および小腸の検査用ｘ線造影剤 |
| US5538989A (en) * | 1993-11-10 | 1996-07-23 | Hoechst-Roussel Agri-Vet Company | Fenbendazole formulations |
| JP4012994B2 (ja) * | 1996-05-08 | 2007-11-28 | 大塚製薬株式会社 | 抗不安薬 |
| JP3952681B2 (ja) | 2000-10-10 | 2007-08-01 | 味の素株式会社 | 分岐鎖アミノ酸を含有する医薬用懸濁剤 |
| JP2003081882A (ja) | 2001-09-10 | 2003-03-19 | Kyosei Seiyaku Kk | 硫酸バリウムｘ線造影剤 |
| US6987111B2 (en) | 2003-08-06 | 2006-01-17 | Alkermes Controlled Therapeutics, Ii | Aripiprazole, olanzapine and haloperidol pamoate salts |
| CN100518806C (zh) | 2003-10-02 | 2009-07-29 | 兴和株式会社 | 医药组合物 |
| ES2315721T5 (es) | 2003-10-23 | 2012-08-24 | Otsuka Pharmaceutical Co., Ltd. | Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento |
| TWI371274B (en) | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
| ATE424816T1 (de) * | 2003-10-27 | 2009-03-15 | Dow Corning | Zubereitungen für die topische anwendung und verfahren zur abgabe eines wirkstoffs an ein substrat |
| GB0328693D0 (en) | 2003-12-11 | 2004-01-14 | Ici Plc | Metal oxide dispersions |
| JP4315393B2 (ja) | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| EP2502621A1 (en) * | 2005-06-27 | 2012-09-26 | Valeant International (Barbados) SRL | Crystalline forms of bupropion HBr |
| EP1933814A2 (en) | 2005-09-15 | 2008-06-25 | Elan Pharma International Limited | Nanoparticulate aripiprazole formulations |
| JP4373983B2 (ja) | 2006-01-27 | 2009-11-25 | 三菱電機インフォメーションシステムズ株式会社 | 流通経路管理装置及び流通経路管理プログラム |
| JP2010505819A (ja) * | 2006-10-05 | 2010-02-25 | パナセア バイオテック リミテッド | デポ型注射剤組成物とその調製方法 |
| JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| BRPI0717721A2 (pt) | 2006-11-28 | 2013-10-29 | Marinus Pharmaceuticals | "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho" |
| UA97286C2 (ru) * | 2007-07-31 | 2012-01-25 | Оцука Фармасьютикал Ко., Лтд. | Способ изготовления суспензии арипипразола и лиофилизированного состава |
| JP2011136906A (ja) * | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
| JP2010013364A (ja) | 2008-07-01 | 2010-01-21 | Tsujido Chemical Corp | 高尿酸血症の予防または改善剤 |
-
2011
- 2011-08-19 MY MYPI2012700825A patent/MY174552A/en unknown
- 2011-08-19 NZ NZ603076A patent/NZ603076A/en unknown
- 2011-08-19 TW TW100129758A patent/TWI589301B/zh active
- 2011-08-19 ES ES11755155.6T patent/ES2685469T3/es active Active
- 2011-08-19 MX MX2012014646A patent/MX344235B/es active IP Right Grant
- 2011-08-19 WO PCT/JP2011/069243 patent/WO2012026562A1/en active Application Filing
- 2011-08-19 AR ARP110103020A patent/AR082494A1/es not_active Application Discontinuation
- 2011-08-19 AU AU2011294201A patent/AU2011294201B2/en active Active
- 2011-08-19 UA UAA201303627A patent/UA107031C2/uk unknown
- 2011-08-19 JP JP2012547778A patent/JP5575269B2/ja active Active
- 2011-08-19 CA CA2796755A patent/CA2796755C/en active Active
- 2011-08-19 BR BR112012028368A patent/BR112012028368B8/pt active IP Right Grant
- 2011-08-19 RU RU2013113033/15A patent/RU2535089C2/ru active
- 2011-08-19 CN CN201180035800.1A patent/CN103025318B/zh active Active
- 2011-08-19 KR KR1020127028730A patent/KR101461769B1/ko active IP Right Grant
- 2011-08-19 SG SG2012076667A patent/SG184879A1/en unknown
- 2011-08-19 US US13/642,046 patent/US9511022B2/en active Active
- 2011-08-19 EP EP11755155.6A patent/EP2552420B1/en active Active
-
2012
- 2012-10-23 IL IL222628A patent/IL222628A/en active IP Right Grant
- 2012-12-07 CO CO12222691A patent/CO6640304A2/es unknown
-
2016
- 2016-11-01 US US15/340,059 patent/US20170112830A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX344235B (es) | 2016-12-07 |
| KR101461769B1 (ko) | 2014-11-13 |
| CA2796755A1 (en) | 2012-03-01 |
| ES2685469T3 (es) | 2018-10-09 |
| EP2552420B1 (en) | 2018-07-18 |
| JP5575269B2 (ja) | 2014-08-20 |
| MX2012014646A (es) | 2013-02-07 |
| UA107031C2 (uk) | 2014-11-10 |
| JP2013525263A (ja) | 2013-06-20 |
| AU2011294201A1 (en) | 2012-11-08 |
| SG184879A1 (en) | 2012-11-29 |
| BR112012028368B1 (pt) | 2020-08-04 |
| US9511022B2 (en) | 2016-12-06 |
| MY174552A (en) | 2020-04-24 |
| CN103025318A (zh) | 2013-04-03 |
| BR112012028368B8 (pt) | 2022-07-19 |
| WO2012026562A1 (en) | 2012-03-01 |
| CA2796755C (en) | 2015-10-27 |
| EP2552420A1 (en) | 2013-02-06 |
| US20130045250A1 (en) | 2013-02-21 |
| BR112012028368A2 (pt) | 2017-03-21 |
| NZ603076A (en) | 2014-12-24 |
| KR20120136415A (ko) | 2012-12-18 |
| TW201212940A (en) | 2012-04-01 |
| CN103025318B (zh) | 2016-07-06 |
| TWI589301B (zh) | 2017-07-01 |
| US20170112830A1 (en) | 2017-04-27 |
| IL222628A (en) | 2017-10-31 |
| IL222628A0 (en) | 2012-12-31 |
| AU2011294201B2 (en) | 2015-08-27 |
| RU2535089C2 (ru) | 2014-12-10 |
| RU2013113033A (ru) | 2014-09-27 |
| CO6640304A2 (es) | 2013-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082494A1 (es) | Composicion en torta y en suspension con contenido de derivado de carbostirilo y derivado de aceite de silicona y/o aceite de silicona | |
| EA201290482A1 (ru) | Стабильные составы для лиофилизации терапевтических частиц | |
| EA201400869A1 (ru) | Масляная дисперсия, способ её получения, упаковка и применение борной кислоты в качестве стимулятора консервации масляной дисперсии | |
| EA201190092A1 (ru) | Композиции с отсроченным высвобождением для перорального применения, содержащие аморфный бардоксолон метил (cddo-me) | |
| MX2020007227A (es) | Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa. | |
| BR112014009131A8 (pt) | formulações de etanercept estabilizadas com meglumina | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| WO2013179307A3 (en) | Stabilized pharmaceutical compositions of saxagliptin | |
| BR112015006017A2 (pt) | estabilização de sistemas de cápsulas em produtos de lavagem e outros produtos de limpeza | |
| BR112013030686A2 (pt) | composição para tratamento dos cabelos límpida que compreende óleo- base e silicone | |
| AR085527A1 (es) | Una composicon farmaceutica para tratar una enfermedad en la cavidad oral que comprende rebamipida | |
| MX2009013536A (es) | Una nueva composicion coadyuvante a base de aceite. | |
| BR112012024131A2 (pt) | Emulsões úteis em bebidas. | |
| BR112012022101A2 (pt) | agente para melhorar a deposição de óleo sobre os cabelos. | |
| EA201591433A1 (ru) | Офтальмологические составы | |
| UA110979C2 (uk) | Рідка фармацевтична композиція, яка включає нітизинон | |
| WO2013007637A3 (en) | Cosmetic compositions in the form of water-in-oil emulsions including a jasmonic acid derivative and a silicone surfactant | |
| EA201391198A1 (ru) | Несмываемая, нетвердая, кондиционирующая кожу композиция, которая имеет диспергирующую масляную фазу и содержит 12-гидроксистеариновую кислоту | |
| WO2014097258A3 (en) | Aqueous cosmetic composition comprising alkylcellulose | |
| MX346407B (es) | Composiciones cosmeticas de aceite-en-agua. | |
| MX2011008324A (es) | Composiciones que contienen 1,2-benzisotiazolin-3-ona. | |
| EA201590673A1 (ru) | Слоистые двойные гидроксиды | |
| BR112013027279A2 (pt) | componente de formulação | |
| BR112018001621A2 (pt) | composições fluidas viscoelásticas, composições escoáveis em óleo/de dispersão em óleo e composições fluidas para perfuração | |
| CL2015000847A1 (es) | Formulaciones de aceite con aglutinantes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |